Quick Answer
Aldeyra Therapeutics, Inc. reported Net Income Loss of -$33.85 million for the year ending 2025.
- Aldeyra Therapeutics, Inc. showed an increase of +39.4% in Net Income Loss from 2024 to 2025.
- This data is from Aldeyra Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Aldeyra Therapeutics, Inc.'s Net Income Loss has declined by 359.2%.
- Historical annual values: Fiscal year 2025: -$33.85 million | Fiscal year 2024: -$55.85 million | Fiscal year 2023: -$37.54 million | Fiscal year 2022: -$62.02 million | Fiscal year 2021: -$57.78 million | Fiscal year 2020: -$37.55 million | Fiscal year 2019: -$60.83 million | Fiscal year 2018: -$38.89 million | Fiscal year 2017: -$22.34 million | Fiscal year 2016: -$18.70 million | Fiscal year 2015: -$12.09 million | Fiscal year 2014: -$5.19 million | Fiscal year 2013: $13.06 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: